Xlife Sciences AG
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies

Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery), signed an exclusive license agreement. Novaxomx has obtained the exclusive rights to use Lysatpharma’s patented “exosome” technology for the research of optimizing biomimetic osteoconductive carrier materials by biologizing them with exosomes.

Novaxomx focuses on the research, development, certification, production, and marketing of disruptive, biosurgical therapies for use in musculoskeletal diseases and tissue regeneration. It’s ambition is to improve the carriers’ biofunctionality in regenerative processes such as non-union or delayed non-union fractures or bone fusion after spinal fusion procedures. Other possible applications include the treatment of chronic osteomyelitis, rheumatoid arthritis, or periodontal bone loss.

The bioactive nanovesicles are secreted from human stem cells or derived from autologous platelets. They are introduced with the carrier materials and enable intercellular communication, which is crucial for regenerative processes in the human body.

Frank Plöger, Chief Scientific Officer of Xlife Sciences AG and Managing Director of Lysatpharma GmbH, says: “Xlife Sciences and curasan founded Novaxomx in March 2022. Since then, we made already valuable progress, resulting in the licence agreement we announced today. We look forward to continuing to work on this promising R&D project, aiming at improve patients lives. Furthermore, the agreement is also another proofpoint of the continuously increasing number of research projects and achieved synergies within the broad Xlife universe.”

Dr. Dirk Dembski, CEO of curasan AG, comments: “The license Novaxomx has obtained from Lysatpharma allows Novaxomx to take an interdisciplinary approach to develop disruptive, biosurgical products that fundamentally improve bone healing. We expect that curasan's clinically proven products can then be used even more effectively for bone regeneration thanks to the targeted, innovative biologization option.”

Financial calendar

Annual Report 2022                     April 20, 2023

Ordinary AGM 2023                     June 22, 2023

Half-Year Report 2023                 September 21, 2023

Contact:

Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS) 

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch 

Disclaimer 

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.